A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2018
Price : $35 *
At a glance
- Drugs MSC 2363318A (Primary) ; Tamoxifen; Trastuzumab
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors EMD Serono
- 18 Sep 2018 Status changed from active, no longer recruiting to completed.
- 26 Jul 2018 Planned End Date changed from 9 Jul 2018 to 7 Aug 2018.
- 26 Jul 2018 Planned primary completion date changed from 9 Jul 2018 to 7 Aug 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History